{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wistinghausen B"],"funding":["NCI NIH HHS"],"pagination":["1116-1127"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10909726"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(5)"],"pubmed_abstract":["<h4>Abstract</h4>Posttransplant lymphoproliferative disease (PTLD) in pediatric solid organ transplant (SOT) recipients is characterized by uncontrolled proliferation of Epstein-Barr virus-infected (EBV+) B cells due to decreased immune function. This study evaluated the feasibility, safety, clinical and immunobiological outcomes in pediatric SOT recipients with PTLD treated with rituximab and third-party latent membrane protein-specific T cells (LMP-TCs). Newly diagnosed (ND) patients without complete response to rituximab and all patients with relapsed/refractory (R/R) disease received LMP-TCs. Suitable LMP-TC products were available for all eligible subjects. Thirteen of 15 patients who received LMP-TCs were treated within the prescribed 14-day time frame. LMP-TC therapy was generally well tolerated. Notable adverse events included 3 episodes of rejection in cardiac transplant recipients during LMP-TC therapy attributed to subtherapeutic immunosuppression and 1 episode of grade 3 cytokine release syndrome. Clinical outcomes were associated with disease severity. Overall response rate (ORR) after LMP-TC cycle 1 was 70% (7/10) for the ND cohort and 20% (1/5) for the R/R cohort. For all cohorts combined, the best ORR for LMP-TC cycles 1 and 2 was 53% and the 2-year overall survival was 70.7%. vβT-cell receptor sequencing showed persistence of adoptively transferred third-party LMP-TCs for up to 8 months in the ND cohort. This study establishes the feasibility of administering novel T-cell therapies in a cooperative group clinical trial and demonstrates the potential for positive outcomes without chemotherapy for ND patients with PTLD. This trial was registered at www.clinicaltrials.gov as #NCT02900976 and at the Children's Oncology Group as ANHL1522."],"journal":["Blood advances"],"pubmed_title":["Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study."],"pmcid":["PMC10909726"],"funding_grant_id":["U10 CA180886","P50 CA126752","U10 CA180899"],"pubmed_authors":["Barkauskas DA","Jerkins LP","Pezzella G","Hayashi RJ","Allen CE","Chansky P","Kinoshita H","Abhyankar H","Tanna J","Bollard CM","Saguilig L","Toner K","Wistinghausen B","Karri V","Hanley P","Scull B","Hermiston ML"],"additional_accession":[]},"is_claimable":false,"name":"Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.","description":"<h4>Abstract</h4>Posttransplant lymphoproliferative disease (PTLD) in pediatric solid organ transplant (SOT) recipients is characterized by uncontrolled proliferation of Epstein-Barr virus-infected (EBV+) B cells due to decreased immune function. This study evaluated the feasibility, safety, clinical and immunobiological outcomes in pediatric SOT recipients with PTLD treated with rituximab and third-party latent membrane protein-specific T cells (LMP-TCs). Newly diagnosed (ND) patients without complete response to rituximab and all patients with relapsed/refractory (R/R) disease received LMP-TCs. Suitable LMP-TC products were available for all eligible subjects. Thirteen of 15 patients who received LMP-TCs were treated within the prescribed 14-day time frame. LMP-TC therapy was generally well tolerated. Notable adverse events included 3 episodes of rejection in cardiac transplant recipients during LMP-TC therapy attributed to subtherapeutic immunosuppression and 1 episode of grade 3 cytokine release syndrome. Clinical outcomes were associated with disease severity. Overall response rate (ORR) after LMP-TC cycle 1 was 70% (7/10) for the ND cohort and 20% (1/5) for the R/R cohort. For all cohorts combined, the best ORR for LMP-TC cycles 1 and 2 was 53% and the 2-year overall survival was 70.7%. vβT-cell receptor sequencing showed persistence of adoptively transferred third-party LMP-TCs for up to 8 months in the ND cohort. This study establishes the feasibility of administering novel T-cell therapies in a cooperative group clinical trial and demonstrates the potential for positive outcomes without chemotherapy for ND patients with PTLD. This trial was registered at www.clinicaltrials.gov as #NCT02900976 and at the Children's Oncology Group as ANHL1522.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-01T03:22:01.659Z","creation":"2026-07-01T03:12:11.174Z"},"accession":"S-EPMC10909726","cross_references":{"pubmed":["38163318"],"doi":["10.1182/bloodadvances.2023010832"]}}